Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine

Michael Goggins, Ralph H. Hruban, Scott E. Kern, BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. American Journal of Pathology. ,vol. 156, pp. 1767- 1771 ,(2000) , 10.1016/S0002-9440(10)65047-X

Buchler M, Korc M, Kobrin Ms, Yamanaka Y, Friess H, Beger Hg, Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Research. ,vol. 13, pp. 565- 569 ,(1993)

Timothy A Yap, Lynn Bjerke, Paul A Clarke, Paul Workman, Drugging PI3K in cancer: refining targets and therapeutic strategies. Current Opinion in Pharmacology. ,vol. 23, pp. 98- 107 ,(2015) , 10.1016/J.COPH.2015.05.016

Deepthi Bhupathi, Dharmendra Ahluwalia, Wenwu Li, Charles P Hart, Fanying Meng, Mark D Matteucci, Qian Liu, Yan Wang, Jessica D Sun, Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. American Journal of Cancer Research. ,vol. 5, pp. 2139- 2155 ,(2015)

Maria Serova, Annemilaï Tijeras-Raballand, Célia Dos Santos, Miguel Albuquerque, Valerie Paradis, Cindy Neuzillet, Karim A. Benhadji, Eric Raymond, Sandrine Faivre, Armand de Gramont, Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients Oncotarget. ,vol. 6, pp. 21614- 21627 ,(2015) , 10.18632/ONCOTARGET.4308

Mark S Talamonti, Christine A Iacobuzio-Donahue, Michael A Hollingsworth, Jen Jen Yeh, Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, Katherine A Hoadley, Naim U Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung, Jadwiga K Smyla, Judy M Anderson, Hong Jin Kim, David J Bentrem, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma Nature Genetics. ,vol. 47, pp. 1168- 1178 ,(2015) , 10.1038/NG.3398

Binhua P. Zhou, Yong Liao, Weiya Xia, Yiyu Zou, Bill Spohn, Mien-Chie Hung, HER-2 / neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation Nature Cell Biology. ,vol. 3, pp. 973- 982 ,(2001) , 10.1038/NCB1101-973

Ralph H. Hruban, Scott E. Kern, Michael Goggins, Jennifer Parsons, Progression Model for Pancreatic Cancer Clinical Cancer Research. ,vol. 6, pp. 2969- 2972 ,(2000)

Jack P. Wang, Chen-Yi Wu, Yi-Cheng Yeh, Yi-Ming Shyr, Ying-Ying Wu, Chen-Yu Kuo, Yi-Ping Hung, Ming-Huang Chen, Wei-Ping Lee, Jiing-Chyuan Luo, Yee Chao, Chung-Pin Li, Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial Oncotarget. ,vol. 6, pp. 18162- 18173 ,(2015) , 10.18632/ONCOTARGET.4216

Ralph H Hruban, Anirban Maitra, Michael Goggins, Update on pancreatic intraepithelial neoplasia. International Journal of Clinical and Experimental Pathology. ,vol. 1, pp. 306- 316 ,(2008)